Cantor Fitzgerald reaffirmed their overweight rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research report released on Tuesday,Benzinga reports.
Other equities analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Belite Bio in a research report on Tuesday. Benchmark increased their target price on shares of Belite Bio from $57.00 to $79.00 and gave the stock a “buy” rating in a report on Tuesday, January 21st.
Get Our Latest Analysis on Belite Bio
Belite Bio Trading Up 0.8 %
Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Equities research analysts forecast that Belite Bio will post -1.17 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Advisors Preferred LLC bought a new stake in shares of Belite Bio during the 4th quarter worth approximately $52,000. GAMMA Investing LLC increased its holdings in Belite Bio by 48.1% during the fourth quarter. GAMMA Investing LLC now owns 1,290 shares of the company’s stock worth $81,000 after buying an additional 419 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Belite Bio in the fourth quarter valued at $155,000. XTX Topco Ltd bought a new position in shares of Belite Bio in the 3rd quarter valued at about $253,000. Finally, JPMorgan Chase & Co. grew its position in shares of Belite Bio by 7,122.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company’s stock valued at $298,000 after acquiring an additional 6,268 shares during the period. 0.53% of the stock is currently owned by institutional investors.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- How to find penny stocks to invest and trade
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Following Congress Stock Trades
- 3 Must-Own Stocks to Build Wealth This Decade
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.